Santa Monica-based Kite, a Gilead Co., announced Aug. 27 it had received permission to market its cell-based cancer therapy in Europe.
The European Commission has authorized the sale of Kite’s personalized CAR-T immunotherapy for adults with non-Hodgkin’s lymphoma in 28 countries within the European Union.
The Yescarta cell therapy was approved by the U.S. Food and Drug Administration in October 2017, three months after Gilead Sciences Inc. of Foster purchased Kite Pharma Inc. for $11.9 billion.
Health business reporter Dana Bartholomew can be reached at firstname.lastname@example.org. Follow him on Twitter @_DanaBart.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- European Regulators Give an Early Nod to Cancer Treatments From Puma, Kite
- Kite, a Gilead Co., of Santa Monica, Expands in Europe
- Kite Wins Approval to Sell Blood Cancer Treatment in the U.K.
- Gilead Sciences and Kite Pharma Acquire Cell Design Labs
- Kite Will Pay up to $3 Billion for Experimental Cancer Therapy
- Gilead Buys Santa Monica’s Kite Pharma in $12 Billion Cancer-Drug Deal
- Kite Adds Production in Europe
- Key Deals: Kite Pharma Acquired by Gilead Sciences for $12 Billion